Compositions that increase the bioavailability of dihydromyricetin are presented. The bioavailability is increased by methods including formulating dihydromyricetin in nanoparticle form, delivering dihydromyricetin with permeabilizers, and encapsulating dihydromyricetin with an enteric coating.

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

The present invention relates to a mixed-charge nanoparticle for inducing selective death of cancer cells and a use thereof. The mixed-charge nanoparticle of the present invention is localized and crystallized specifically in cancer cell lysosomes through a pH-dependent aggregation behavior due to the balance between positively charged ligands and negatively charged ligands on the surface thereof and can induce lysosomal membrane permeabilization (LMP) and lysosomal cell death mediated thereby, like cationic amphiphilic drugs (CADs) Exhibiting a cancer cell-specific death effect, the nanoparticles of the present invention can surmount the limited medical use of conventional cationic nanoparticles due to the non-specific cytotoxicity thereof. Particularly, the nanoparticles of the present invention do not exhibit toxicity to the human body and normal cells, thus finding useful applications in medical and medicinal uses such as for prevention and treatment of solid cancer, blood cancer, and tumors.

The present invention relates to a mixed-charge nanoparticle for inducing selective death of cancer cells and a use thereof. The mixed-charge nanoparticle of the present invention is localized and crystallized specifically in cancer cell lysosomes through a pH-dependent aggregation behavior due to the balance between positively charged ligands and negatively charged ligands on the surface thereof and can induce lysosomal membrane permeabilization (LMP) and lysosomal cell death mediated thereby, like cationic amphiphilic drugs (CADs) Exhibiting a cancer cell-specific death effect, the nanoparticles of the present invention can surmount the limited medical use of conventional cationic nanoparticles due to the non-specific cytotoxicity thereof. Particularly, the nanoparticles of the present invention do not exhibit toxicity to the human body and normal cells, thus finding useful applications in medical and medicinal uses such as for prevention and treatment of solid cancer, blood cancer, and tumors.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

The present disclosure provides a nutritional formula comprising alpha-lactalbumin enriched whey protein concentrate; beta-casein enriched milk protein; mildly hydrolyzed milk protein; osteopontin; lactoferrin; oleic acid-palmitic acid-oleic acid triglyceride, wherein palmitic acid is at the SN-2 position of the glycerol backbone of the triglyceride; lactose, wherein the lactose is reduced lactose; lutein; docosahexanoic acid; arachidonic acid; galactooligosaccharides; and polydextrose. The provided nutritional formulas may be useful in providing nutrition and/or promoting postnatal development of a subject (e.g., promoting postnatal development of an infant's gastrointestinal functions, nutrient absorption, immune system development, etc.). Also provided are powder forms, reconstituted formulas, kits, methods, and uses that include or involve a nutritional formula described herein.

Provided is a Lactiplantibacillusplantarum TCI837, deposited in the Leibniz Institute DSMZ under an accession number of DSM 33843. Based on this, the Lactiplantibacillusplantarum TCI837 can be used to prepare a composition for supplementing iron and/or promoting the absorption of iron in a subject, and to prepare a composition for improving the gut microbiota in a subject. In addition, the composition may be an iron supplement composition containing the Lactiplantibacillusplantarum TC1837 and an iron supplement.

Provided is a Lactiplantibacillusplantarum TCI837, deposited in the Leibniz Institute DSMZ under an accession number of DSM 33843. Based on this, the Lactiplantibacillusplantarum TCI837 can be used to prepare a composition for supplementing iron and/or promoting the absorption of iron in a subject, and to prepare a composition for improving the gut microbiota in a subject. In addition, the composition may be an iron supplement composition containing the Lactiplantibacillusplantarum TC1837 and an iron supplement.